Forest Laboratories Inc

Forest Laboratories — Proxy Contest (August 2011)

13 slides from Forest Laboratories's proxy contest presentation, Aug 4, 2011

  1. Slide 1: Forest 2011 Annual Meeting website welcome page

    £| Forest 2011 Annual Meeting — Windows Internet Explorer provided by SARD VERBINNEN & CO | 1=1 | LJ |—“fll^ J <* £2j http:/Aw/V/.fnx2011annualmeeting.com’ T ^ 4*f X *¦* Google <P T File Edit View Favorites Tools Help <£ Favorites ^ Forest 2011 Annual Meeting /jLvSP Forest Laboratories* Inc. visitfm

  2. Slide 2: SEC Filings list

    $ SEC Filings | Forest 2011 Annual Meeting — Windows Internet Explorer provided by SARD VERBINNEN & CO | 1=1 | LJ |ww%wj .’ w J?j http:/..’www.frx2011annualmeeting.com-’sec-filings/ T ^ 4*f X *¦* Google <P T File Edit View Favorites Tools Help <Q Favorites &nb sp; gfi SEC Filings | Forest 2D11 Annua

  3. Slide 3: SEC Filings list (continued)

    ££ SEC Filings | Forest 2011 Annual Meeting — Windows Internet Explorer provided by SARD VERBiNNEN & CO | 1=1 | LJ |ww%wj .’ w J?j http:/..’www.frx2011annualmeeting.com-’sec-filings/ T ^ 4*f X *¦* Google <P T File Edit View Favorites Tools Help <£ Favorites £fi SEC Filings | Forest 2011 Annual Meeti

  4. Slide 4: Presentations & Materials

    0 Presentations & Materials | Forest 2011 Annual Meeting — Windows Internet Explorer provided by SARD VERBINNEN & CO j ? |Jj ht ±p:/..’v;\lvW.frK2011annualmeeting.conn.’pre:entation!;-material:/ T ^ ^f X «’ Googte <P T : File Edit View Favorites TcoIe Help <Q Favorites & nbsp; fjg Presentations & Ma

  5. Slide 5: Presentations & Materials (continued)

    £ Presentations & Materials | Forest 2011 Annual Meeting — Windows Internet Explorer provided by SARD VERBINNEN & CO j ? |Jj http://\wvW.fnx2011annualmeeting.conn.’presentation!;-material:/ T ^ ^f X «’ Googte <P T File Edit View Favorites Tools Help £? Favorites ^ Presentations & Materials | Forest

  6. Slide 6: Icahn's August 3rd Claims Are Filled With Misrepresentations

    Forest Labs Icahn's August 3rd Claims Are Filled With Misrepresentations August 4, 2011

  7. Slide 7: In His August 3rd Filing, Icahn...

    In His August 3rd Filing, Icahn: Asks Forest shareholders to ignore Denner's and Mulligan's obvious board conflicts Presents misleading conflict of interest data about Forest and other companies Uses misleading Forest share price performance data by selecting a completely arbitrary time frame and by

  8. Slide 8: Denner and Mulligan Are Conflicted

    Denner and Mulligan Are Conflicted Icahn doesn't challenge the fact that Biogen Idec and Amylin compete with Forest in important therapeutic areas Biogen Idec website: "We are interested in partnerships in our core therapeutic areas of neurology and other areas of high unmet need. In addition, we we

  9. Slide 9: Icahn Misrepresents Conflict of Interest Data

    Icahn Misrepresents Conflict of Interest Data Icahn erroneously states that Forest has no guidelines on "unacceptable conflicts." We believe that ALL conflicts are unacceptable Our guidelines regarding conflicts are clear and available on our website: "No Director shall serve as a director, officer

  10. Slide 10: Icahn's Share Price Performance Data is Misleading

    Icahn's Share Price Performance Data is Misleading Forest has presented consistent data demonstrating short- and long-term outperformance against both the S&P 500 and the AMEX Pharmaceutical Index (DRG) In contrast, Icahn: Opportunistically selects 7-year performance data and excludes the most recen

  11. Slide 11: We have outperformed the most relevant indices

    We have outperformed the most relevant indices - the S&P 500 and the DRG - over both the short-term and long-term Icahn Unfairly Criticizes our Share Price Performance Notes The AMEX Pharmaceutical Index (DRG) was developed on July 31, 1991 Price performance does not include dividends Price Performa

  12. Slide 12: Research Analysts Respect Forest's Accomplishments

    Research Analysts Respect Forest's Accomplishments Icahn has endorsed a research analyst who is an outlier with a long-held, consistently negative view of the Company. Most other Forest sell-side analysts disagree: Corey Davis, Jefferies Research, 5/16/11: "Best late stage pipeline in all biopharma

  13. Slide 13: Important Additional Information

    Important Additional Information Forward Looking Information Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertaint

Forest Laboratories — Proxy Contest (August 2011) on 6ix